- Siegfried acquires Curia Global’s early-phase CDMO site in Grafton, WI, to enhance its development and manufacturing services.
- The acquisition is expected to close by July 1, 2024, expanding Siegfried’s U.S. presence and capabilities.
Siegfried, a global contract development and manufacturing organization (CDMO) headquartered in Zofingen, Switzerland, has signed agreements with Curia Global for the acquisition of an early-phase CDMO site in Grafton, WI. The transaction is expected to close by July 1, 2024.
The newly acquired site specializes in early-phase development and manufacturing services and employs over 80 personnel. This move is set to strengthen Siegfried’s capabilities in drug substance development and manufacturing, enhancing their geographical coverage and service offering. Siegfried plans to transform the Grafton site into a best-in-class hub for early-phase CDMO services, including projects with highly potent APIs.
“With this acquisition, we enhance our offering with early-stage development services for drug substances and become even more relevant and attractive to our customers,” said Reto Suter, CEO ad interim and CFO of Siegfried. “Siegfried now offers an integrated range of services from early-stage development to commercial production of APIs through to the manufacturing of fully formulated drug products.”
The acquisition will bolster Siegfried’s presence in the U.S., the world’s largest pharmaceutical market. It will allow Siegfried to provide comprehensive support to customers in the pre-clinical and clinical development and manufacturing of drug substances. The deal also broadens Siegfried’s services, particularly benefiting small and medium-sized pharmaceutical companies.
Overview of outsourcing trends 
